Skip to main content

Table 3 Effect of azithromycin on changes in sTNFR75 levels at 3 months according to subgroups

From: Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori

Subgroup

 

sTNFR75 level (μg/L)

p-value*

N

Baseline

3 months

Difference

HP +

76

8.65 ± 0.50

7.78 ± 0.45

−0.87 ± 0.31

0.002

HP -

356

8.52 ± 0.24

8.63 ± 0.32

0.11 ± 0.25

0.64

Total

432

8.54 ± 0.22

8.48 ± 0.27

−0.06 ± 0.21

0.10

Ex-smoker

360

8.73 ± 0.24

8.56 ± 0.31

−0.17 ± 0.24

0.03

Smoker

89

8.10 ± 0.41

8.11 ± 0.43

0.01 ± 0.30

0.89

Age > 65

220

8.52 ± 0.29

8.46 ± 0.42

−0.06 ± 0.36

0.25

Age ≤ 65

229

8.68 ± 0.31

8.48 ± 0.32

−0.20 ± 0.20

0.08

GOLD 2

120

9.07 ± 0.39

9.08 ± 0.67

0.01 ± 0.60

0.15

GOLD 3

183

8.68 ± 0.32

8.49 ± 0.34

−0.19 ± 0.22

0.29

GOLD 4

145

8.12 ± 0.40

7.86 ± 0.40

−0.26 ± 0.27

0.19

  1. Data are presented as means ± standard errors of the mean
  2. sTNFR75 soluble tumor necrosis factor-75, GOLD Global Initiative for Chronic Obstructive Lung Disease, HP Helicobacter pylori
  3. *Paired t-tests on log-transformed data
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us